gerenme/iStock via Getty Images Viatris’ ( NASDAQ: VTRS ) Mylan unit is no longer a subject of DOJ’s antitrust investigation in the generic drug industry, the pharmaceutical firm said on Tuesday. In 2017, Mylan’s former president and second-in-command Rajiv Malik was named in a civil lawsuit over colluding to keep generic drug prices high. Dozens of states alleged that Malik played an active role in a price-fixing conspiracy among global generic drugmakers to keep prices artificially inflated.
The DOJ’s civil division informed Viatris ( VTRS ) today that it "doesn’t expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products". Asserting its stance on the matter, Viatris ( VTRS ) said that Mylan investigated these allegations thoroughly and found no evidence of wrongdoing on the part of Mylan or its employees. Shares of the drugmaker were up around 2% premarket on Tuesday.
More on Viatris Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope Viatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Viatris Inc. (VTRS) Presents at Jefferies 2024 Global Healthcare Conference (Transcript) Viatris Non-GAAP EPS of $0.
67 in-line, revenue of $3.66B misses by $30M Viatris Q1 Earnings Preview: Focus remains on capital allocation.
